The assessment of PD‐L1 status in carcinoma cells was usually performed only in primary or metastatic NSCLC cell to determine the possible therapeutic efficacy of PD‐1/PD‐L1 inhibitors.13 This evidence concerns the gene CD274 and carcinoma.